# DESCRIPTION

## FIELD OF INVENTION

- introduce sigma-2 receptor binders

## BACKGROUND OF THE INVENTION

- identify sigma-1 and sigma-2 receptors
- describe physiological properties of SKF-10,047
- determine true function of sigma receptor
- facilitate binding studies of ligands
- identify two distinct subtypes of sigma receptors
- suggest sigma-2 receptor synonymous with PGRMC1
- explore therapeutic utility of sigma-2 receptor binders
- prevent binding of beta amyloid protein oligomers
- displace beta amyloid protein oligomers from neurons
- demonstrate expression of sigma-2 receptor in tumor cells
- modulate sigma-2 receptor activity to induce cancer cell death

## BRIEF SUMMARY OF THE INVENTION

- introduce novel sigma-2 receptor binders
- define compounds of formula (I)
- specify A, n, R1a, R1b, R2, R3, R4, R5, R6, R7
- describe R4 groups on benzene ring
- describe R5 groups on pyridine ring
- specify R8a, R8b, R9a, R9b, R10, R11, R12a, R12b
- relate to compositions comprising compounds
- relate to method for treating neuropsychiatric disorders
- relate to method for treating cancer
- relate to method for treating diseases involving dysregulation
- relate to method for treating diseases involving overexpression
- relate to method for treating or preventing disease or conditions
- relate to process for preparing sigma-2 receptor binders
- describe effective amount of compounds
- describe excipient in composition
- describe administering to a subject

## DETAILED DESCRIPTION OF THE INVENTION

- identify disease states associated with sigma-2 receptor dysregulation
- motivate need for new sigma-2 receptor binders and activity modulators
- introduce invention to address need for therapeutic agents
- describe sigma-2 receptor binders and activity modulators
- specify diseases and disorders treatable by invention
- elaborate on treating and preventing diseases associated with dysregulation
- elaborate on treating and preventing diseases associated with overexpression
- define compositions and processes
- clarify meaning of "including" and "comprising"
- clarify meaning of "about"
- clarify order of steps
- define "halogen"
- define "alkyl" and "aliphatic"
- provide examples of alkyl groups
- define "alkenyl" and "alkynyl"
- provide examples of alkenyl and alkynyl groups
- define "cycloalkyl"
- provide examples of cycloalkyl groups
- define "haloalkyl"
- provide examples of haloalkyl groups
- define "alkoxy"
- define "haloalkoxy"
- define "aryl"
- provide examples of aryl groups
- define "arylalkyl" or "aralkyl"
- define "heterocyclic" and/or "heterocycle" and/or "heterocyclyl"
- provide examples of heterocycle groups
- define heterocyclic units
- provide non-limiting examples of heterocyclic units
- define heteroaryl
- provide non-limiting examples of heteroaryl rings
- define C1-C5 heteroaryl
- provide examples of C1-C5 heteroaryl
- define fused ring units
- provide examples of fused ring units
- define substituents
- provide non-limiting examples of substituents
- define optionally substituted groups
- provide non-limiting examples of substituents
- define R13 and R14
- provide non-limiting examples of R13 and R14
- define substituents in some embodiments
- provide non-limiting examples of substituents in some embodiments
- define R15
- provide non-limiting examples of R15
- define compounds
- define analogs and compositions of matter
- discuss optical isomers
- discuss regioisomers
- discuss pharmaceutically acceptable salts
- provide non-limiting examples of bases for forming salts
- provide non-limiting examples of acids for forming salts
- discuss internal salts
- define treating and treatment
- define terms
- introduce subject patients
- describe screening methods
- introduce sigma-2 receptor binders
- define formula (I)
- describe R1a and R1b
- describe R2
- describe R3
- describe R4
- describe R5
- introduce compounds of formula (II)
- describe compounds of formula (IIa)
- describe compounds of formula (IIb)
- describe compounds of formula (IIc)
- describe compounds of formula (IId)
- conclude sigma-2 receptor binders
- define compounds
- specify formula (III)
- specify formula (IIIa)
- specify formula (IIIb)
- specify formula (IIIc)
- specify formula (IId)
- specify formula (IV)
- specify formula (IVa)
- specify formula (IVb)
- specify formula (IVc)
- specify formula (IVd)
- specify formula (V)
- specify formula (Va)
- specify formula (Vb)
- describe hydrates
- describe solvates
- describe enantiomers
- describe diastereomers
- define compounds having formula Vc
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula Vd
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula VI
- define compounds having formula VIa
- specify R4a, R4b, R4c, R4d, and R4e groups
- define compounds having formula VIb
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula VIc
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula VId
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula VII
- define compounds having formula VIIa
- specify R4a, R4b, R4c, R4d, and R4e groups
- define compounds having formula VIIb, VIIc, VIId, and VIII
- define compounds having formula (VIIIb)
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula (VIIIc)
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula (VIIId)
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula (IX)
- define compounds having formula (IXa)
- specify R4a, R4b, R4c, R4d, and R4e groups
- define compounds having formula (IXb)
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula (IXc)
- specify R5a, R5b, R5c, and R5d groups
- define compounds having formula (IXd)
- specify R5a, R5b, R5c, and R5d groups
- specify A
- specify n
- specify R1a
- specify R1b
- specify R1a and R1b taken together
- specify R2
- specify R3
- specify R4
- specify R4a
- specify R4b and R4c
- define R4c embodiments
- define R4d embodiments
- define R4c embodiments
- define R4d embodiments
- define R4c embodiments
- define R5 embodiments
- define R5a embodiments
- define R5a embodiments
- define R5b embodiments
- define R5b embodiments
- define R5b embodiments
- define R5b embodiments
- define R5b embodiments
- define R5c embodiments
- define R5d embodiments
- define R6 embodiments
- define R7 embodiments
- define R8 and R9 embodiments
- define R9a
- define R9b
- define R9a and R9b taken together
- define R10
- define R11
- define R12a
- define R12b
- list examples of compounds
- define formula II
- define formula X
- define formula XI
- define formula XII
- define formula XIII
- define formula VI
- define formula XIV
- define formula XV
- define formula XVI
- define formula XVII
- provide naming convention
- provide example of naming convention
- provide example of naming convention
- provide enantiomer notation
- provide diastereomer notation
- provide scope of substituents

### Process

- introduce process for preparing sigma-2 receptor binders
- outline standard synthetic methods and procedures
- describe reaction conditions and optimization
- discuss monitoring of product formation
- explain protection and deprotection of chemical groups
- describe selection of suitable solvents
- outline preparation of compounds by known methods
- introduce general synthetic schemes for preparation
- describe reaction schemes for preparing compounds
- outline specific reaction conditions and reagents
- provide examples of palladium catalysts and bases
- react compound 5 with compound 6
- react compound 9 with compound 10
- react compound 13 with compound 14
- react compound 17 with compound 18
- treat compound 19 with paraformaldehyde
- treat compound 20 with base
- convert compound 21 to compound 22
- react compound 22 with compound 23
- react compound 25 with compound 26
- treat compound 27 with paraformaldehyde
- treat compound 28 with base
- convert compound 29 to compound 30
- react compound 30 with compound 31
- prepare compound 37 according to Scheme 7
- react compound 33 with base
- react compound 34 with iodine
- react compound 35 with compound 36
- prepare compound 46 according to Scheme 8
- react compound 38 with ruthenium chloride
- react compound 39 with compound 40
- react compound 41 with ruthenium chloride
- react compound 42 with reducing agent
- convert compound 43 to compound 44
- react compound 44 with compound 45
- provide representative methods for preparing compounds
- substitute reagents and starting materials
- use purification methods
- prepare compounds of the present invention
- react compounds according to Schemes
- treat compounds with reagents
- convert compounds to other compounds
- react compounds with other compounds
- provide examples of preparing compounds

### EXAMPLES

- introduce examples of the invention
- provide representative methods for preparing compounds
- describe experimental conditions
- specify instruments used
- detail procedure for Example 1
- provide NMR and mass spectral data for Example 1
- generalize procedure for other compounds
- detail procedure for Example 2
- provide NMR data for Example 2
- detail procedure for Example 3
- provide NMR and mass spectral data for Example 3
- generalize procedure for other compounds
- detail procedure for Example 4
- provide NMR data for Example 4
- detail procedure for Example 5
- provide NMR data for Example 5
- detail procedure for Example 6
- provide NMR and mass spectral data for Example 6
- generalize procedure for other compounds
- detail procedure for Example 7
- provide NMR data for Example 7
- detail procedure for Example 8
- provide NMR and mass spectral data for Example 8
- detail procedure for Example 9-12
- prepare 2-(5-oxo-6-oxaspiro[3.4]octan-7-yl)ethyl 4
- prepare 2-(1-oxo-2-oxaspiro[4.4]nonan-3-yl)ethyl 4
- prepare 2-(1-oxo-2-oxaspiro[4.5]decan-3-yl)ethyl 4
- prepare 5-(2-bromoethyl)-3,3-diethyldihydrofuran-2(3H)-one
- prepare 3-(2-bromoethyl)-2-oxaspiro[4.5]decan-1-one
- prepare 2,2-diethylpent-4-enoic acid
- prepare 3,3-diethyl-5-(iodomethyl)dihydrofuran-2(3H)-one
- prepare 3-(iodomethyl)-2-oxaspiro[4.4]nonan-1-one
- prepare 3-(iodomethyl)-2-oxaspiro[4.5]decan-1-one
- prepare 3-hydroxy-2-oxaspiro[4.4]nonan-1-one
- prepare 3-hydroxy-2-oxaspiro[4.5]decan-1-one
- prepare 3-(but-3-en-1-yl)-2-oxaspiro[4.4]nonan-1-one
- prepare 3-(but-3-en-1-yl)-2-oxaspiro[4.5]decan-1-one
- prepare 3-(1-oxo-2-oxaspiro[4.4]nonan-3-yl)propyl
- reduce aldehyde
- prepare tosylate
- purify tosylate
- generalize procedure
- generalize procedure
- generalize procedure
- generalize procedure
- generalize procedure
- generalize procedure
- generalize procedure
- generalize procedure
- provide examples
- describe preparation of 3-(1-oxo-2-oxaspiro[4.5]decan-3-yl)prop
- describe preparation of 5-(2-(5-benzylhexahydropyrrolo[3,4-c]pyrrol-2(
- describe preparation of 3-(2-(5-benzylhexahydropyrrolo[3,4-c]pyrrol-2(
- describe preparation of 3,3-diethyl-5-(2-(hexahydropyrrolo[3,4-c]pyrrol-
- describe preparation of 3-(2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl
- describe preparation of 3,3-diethyl-5-(2-(5-(pyridin-4-yl)hexahydropyr
- describe preparation of 3-(2-(5-(pyridin-4-yl)hexahydropyrrolo[3,4-c]
- describe preparation of 1-(benzyloxy)-2-bromobenzene
- describe preparation of 1-(benzyloxy)-3-bromobenzene
- describe preparation of 1-(benzyloxy)-4-bromobenzene
- provide NMR data for example 27
- provide NMR data for other examples
- describe example 37
- describe example 38
- describe example 39
- describe example 40
- describe example 41
- describe example 42
- describe example 43
- describe example 44
- describe example 45
- describe example 46
- provide NMR data
- provide MS data
- provide reaction conditions
- provide examples
- prepare tert-butyl 5-(m-tolyl)hexahydropyrrolo[3,4-c]pyrrole-2(
- prepare tert-butyl 5-(p-tolyl)hexahydropyrrolo[3,4-c]pyrrole-2(
- prepare tert-butyl 5-(2-methoxyphenyl)hexahydropyrrolo[3,4-c]pyrrole-
- prepare tert-butyl 5-(3-methoxyphenyl)hexahydropyrrolo[3,4-c]pyrrole-
- prepare tert-butyl 5-(4-methoxyphenyl)hexahydropyrrolo[3,4-c]pyrrole-
- prepare tert-butyl 5-(2-cyanophenyl)hexahydropyrrolo[3,4-c]pyrrole-
- prepare tert-butyl 5-(3-cyanophenyl)hexahydropyrrolo[3,4-c]pyrrole-
- prepare tert-butyl 5-(4-cyanophenyl)hexahydropyrrolo[3,4-c]pyrrole-
- prepare tert-butyl 5-(2-(benzyloxy)phenyl)hexahydropyrrolo[3,4-c]py
- prepare tert-butyl 5-(3-(benzyloxy)phenyl)hexahydropyrrolo[3,4-c]py
- provide NMR data
- provide MS data
- describe example 57
- describe example 58
- describe example 59
- describe example 60
- describe example 61
- describe example 62
- describe example 63
- describe example 64
- describe example 65
- describe example 66
- provide examples
- prepare 2-(2,6-dimethylpyridin-4-yl)octahydropyrrolo[3,4-c]
- prepare 2-(o-tolyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 2-(m-tolyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 2-(p-tolyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 2-(2-methoxyphenyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 2-(4-methoxyphenyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)benzonitr
- prepare 4-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)benzonitr
- prepare 2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)benzonitr
- prepare 2-(3-methoxyphenyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 2-(2-(benzyloxy)phenyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 2-(3-(benzyloxy)phenyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 2-(4-(benzyloxy)phenyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 4-(2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phen
- prepare 2-(2-isopropylphenyl)octahydropyrrolo[3,4-c]pyrrole
- prepare 3-(2-(6-(pyridin-4-yl)-2,6-diazaspiro[3.3]he
- prepare 3,3-diethyl-5-(2-(6-phenyl-2,6-diazaspiro[3.3]
- prepare 3-(2-(6-phenyl-2,6-diazaspiro[3.3]heptan-2-
- prepare 3,3-diethyl-5-(2-(5-(2-isopropylphenyl)hexahydro
- describe example 86
- describe example 87
- describe example 88
- describe example 89
- describe example 90
- describe example 91
- describe example 92
- describe example 93
- describe example 94
- describe example 95
- provide NMR data for example 86
- provide NMR data for example 87
- provide NMR data for example 88
- provide NMR data for example 89
- provide NMR data for example 90
- provide NMR data for examples 91-95
- describe example 96
- describe example 97
- describe example 98
- describe example 99
- describe example 100
- describe example 101
- describe example 102
- describe example 103
- describe example 104
- describe example 105
- provide NMR data for example 96
- provide NMR data for example 97
- provide NMR data for example 98
- provide NMR data for example 99
- provide NMR data for example 100
- provide NMR data for examples 101-105
- describe example 106
- describe example 107
- describe example 108
- describe example 109
- introduce formulations
- define excipient
- describe role of excipient
- describe pharmaceutical compositions
- list examples of carriers
- describe oral formulations
- describe solid carriers
- describe powders
- describe tablets
- describe capsules
- describe liquid carriers
- describe solutions
- describe suspensions
- describe emulsions
- describe syrups
- describe elixirs
- describe inhaled delivery
- describe parenteral administration
- describe sterile liquid carriers
- describe unit dosage forms
- describe packaging
- describe dosage
- describe therapeutic applications
- describe administration to airways
- describe intranasal or intrabronchial inhalation
- describe aerosol composition
- describe parenteral or intraperitoneal administration
- describe transdermal administration
- introduce transdermal administration
- describe carrier forms
- describe suppository formulations
- describe lipid formulations
- describe combination therapy
- describe treatment methods
- describe pharmaceutical compositions
- introduce procedures
- describe radiolabel binding studies
- describe assay preparation
- describe data analysis
- describe Ki calculation
- describe screening at single concentration

